H.C. Wainwright analyst Yi Chen raised the firm’s price target on EyePoint Pharmaceuticals to $35 from $25 and keeps a Buy rating on the shares. The analyst says EYP-1901 demonstrated statistically non-inferior change in best corrected visual acuity versus aflibercept in the DAVIO 2 trial. The firm increased the probability of approval for EYP-1901 in wet age-related macular degeneration to 65% from 45%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EYPT:
- EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
- EyePoint announces EYP-1901 achieved primary endpoints in Phase 2 trial
- EyePoint reports inducement grants under Nasdaq listing rule
- EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- EyePoint management to meet with Cantor Fitzgerald